NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
Closed Posted
- Opportunity number
- PAR-25-139
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Up to $275,000
Opportunity facts
- Assistance listings
-
- 93.393 Cancer Cause and Prevention Research
- 93.394 Cancer Detection and Diagnosis Research
- 93.395 Cancer Treatment Research
- 93.396 Cancer Biology Research
- 93.399 Cancer Control
- Funding instrument
- Grant
- Categories
-
- Education
- Health
- Eligible applicants
-
- 501(c)(3) Nonprofits
- City/Township Governments
- For Profit Organizations
- Tribal Governments (Federally Recognized)
- Higher Education Inst. (Public)
- Small Businesses
- Independent School Districts
- State Governments
- County Governments
- Public or Indian Housing Auth.
- Other
- Special District Governments
- Tribal Organizations (Not Federally Recognized)
- Non-501(c)(3) Nonprofits
- Higher Education Inst. (Private)
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
This federal grant opportunity from the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism provides support for the early and conceptual stages of these high-risk, high-reward projects. The opportunity is open to 501(c)(3) nonprofits, higher education institutions, governments, small businesses, and others, with a deadline of September 7, 2025.
Recent federal grant awards in related programs have ranged from approximately $200,000 to over $2 million annually, with typical project periods spanning 2-5 years. The research is expected to be conducted primarily at the recipient organizations' facilities across the United States.
Synopsis
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-139-Full-Announcement.html | HTML file |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity